Hence then, the article about late breaking phase 3 data at 2022 aaaai annual meeting show dupixent dupilumab significantly reduced itch and hives in patients with chronic spontaneous urticaria was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria )
Last updated :
Also on site :
- Skanska signs additional contract with existing client to build a data center in USA for USD 228M, about SEK 2.2 billion
- ‘No way out’: Telangana student dies in Germany after jumping from burning apartment on New Year’s Eve
- Switzerland fire latest: King Charles ‘heartbroken’ after 40 killed in ‘horrific’ Crans Montana bar disaster